Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
OrganonOGN 71 EV-to-OCF is 14.90 as of Aug. 02, 2026, which is 11% above its 10-year median of 13.46. GuruFocus rates OGN with a GF Score™ of 71/100 and a GF Value™ of $13.59 (Fairly Valued). The stock has 10 warning signs investors should review. Among 1,008 Drug Manufacturers companies, Organon ranks worse than 55.16% on this metric.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Organon's Enterprise Value is $10,979 Mil.
Organon's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 was $737 Mil. Therefore, Organon's EV-to-OCF for today is 14.90.
The historical rank and industry rank for Organon's EV-to-OCF or its related term are showing as below:
OGN'
s EV-to-OCF Range Over the Past 10 Years
Min: 2.94 Med: 13.46 Max: 24.8
Current: 14.9
During the past 8 years, the highest EV-to-OCF of Organon was 24.80. The lowest was 2.94. And the median was 13.46.
OGN's EV-to-OCF is ranked worse than 55.16% of 1008
companies
in the Drug Manufacturers industry
Industry Median: 10.725
vs OGN: 14.90
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Organon's share price for today is $13.55.
Organon's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.770.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Organon EV-to-OCF Related Terms
Organon EV-to-OCF Historical Data
* Premium members only.
The historical data trend for Organon's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - General subindustry, Organon's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Organon EV-to-OCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Organon's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Organon's EV-to-OCF falls into.
Organon's current Enterprise Value is $10,979 Mil.
Organon's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $737 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Organon (OGN) has a EV-to-OCF of 14.90 as of Aug. 02, 2026. This is 11% above median its historical median of 13.46. Over the past decade, Organon's EV-to-OCF has ranged from 2.94 to 24.80. According to the industry distribution chart, Organon ranks #556 out of 1008 companies in the Drug Manufacturers industry, placing it in the top 55.2%.
Is Organon's EV-to-OCF too high?
Organon's current EV-to-OCF of 14.90 is 11% above median its 10-year median of 13.46. Over the past 10 years, this metric has ranged from a low of 2.94 to a high of 24.80. The Drug Manufacturers industry median EV-to-OCF is 10.73. Organon's value of 14.90 is 38.9% above this industry median. Based on the distribution chart, Organon ranks #556 out of 1008 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Organon has a GF Score™ of 71/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Organon's EV-to-OCF compare to AMRN and SCLX?
According to the Drug Manufacturers industry distribution chart, Organon ranks #556 out of 1008 companies for EV-to-OCF. This places Organon in the lower half of its industry. The industry median EV-to-OCF is 10.73. Organon's value of 14.90 is 38.9% above this benchmark. Historically, Organon's own EV-to-OCF has ranged from 2.94 to 24.80 over the past decade. While the company's 10-year median is 13.46 vs. the industry median of 10.73, Organon has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Drug Manufacturers company?
The median EV-to-OCF among Drug Manufacturers companies is 10.73, based on 1,008 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-OCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Organon's current EV-to-OCF of 14.90 is 38.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median EV-to-OCF is 10.73 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Organon's current EV-to-OCF is 14.90, which is 11% above median its own 10-year median of 13.46. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Organon stock overvalued right now?
Based on GuruFocus' analysis, Organon (OGN) is currently considered Fairly Valued. The stock's GF Value™ is $13.59, compared to a current price of $13.55 — trading 0.3% below its estimated fair value. The current EV-to-OCF is 14.90, which is 11% above median its 10-year median of 13.46 and 38.9% above the Drug Manufacturers industry median of 10.73. Organon's overall GF Score™ is 71/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Organon (OGN), the current EV-to-OCF is 14.90 as of Aug. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Organon (OGN) Overvalued in 2026?
Based on GuruFocus' analysis, Organon stock appears to be undervalued.
The current stock price of $13.55 is trading 0.3% below its estimated GF Value™ of $13.59.
GuruFocus considers Organon to be Fairly Valued.
Key valuation signals for OGN:
EV-to-OCF: 14.90 (11% above median its 10-year median of 13.46)
GF Value™: $13.59 vs. price of $13.55 (0.3% below fair value)
Industry Position: 38.9% above the Drug Manufacturers median (#556 of 1008)
No single metric tells the full story. See the OGN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Organon & Cois a globalised healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day. Its operations include the following product portfolios: Women's Health: Itbwomen's health portfolio of products is sold by prescription mainly in two therapeutic areas: contraception, with key brands such as Nexplanon, and fertility, with key brands such as Follistim. other women's health products include the Jada, which is intended to provide control and treatment of abnormal postpartum uterine bleeding or hemorrhage when conservative management is warranted. The General Medicines portfolio includes biosimilars and established brands. Companies' current biosimilars portfolio spans across immunology and oncology-related treatments.
71GF Score
Get the complete analysis for OGN
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OGN has been successfully added to your 
